Thymosin Alpha-1 and Thymalfasin: Identity, Human Evidence, and FDA Status

Last evidence review: August 27, 2026

Thymosin alpha-1, often shortened to Ta1, is an N-terminally acetylated 28-amino-acid peptide. FDA’s 2024 review states that thymalfasin is a chemically synthesized version with the same amino-acid sequence as natural Ta1, so the names can be used interchangeably for the defined peptide.[1]

That identity relationship does not make every product interchangeable. FDA separately evaluated Ta1 free base and Ta1 acetate. A finished drug marketed in another country, a compounded preparation, a bulk substance, and a research catalog vial can differ in salt form, formulation, manufacturing controls, impurities, stability, and quality documentation.

This page summarizes molecular identity, selected direct human research, and current U.S. regulatory records. It does not provide medical advice or use instructions.

Identity at a glance

The presence of a UNII or foreign product name does not establish U.S. FDA approval.

Is thymalfasin the same as thymosin alpha-1?

For the defined peptide sequence, FDA’s review says chemically synthesized thymalfasin is identical in amino-acid sequence to natural thymosin alpha-1.[1] The same review warns that Zadaxin, a finished product available in other countries, cannot be used interchangeably with the bulk-substance names.

The catalog question is therefore not solved by the word “thymalfasin.” A product record still needs to state its exact sequence, N-terminal acetylation, C-terminal chemistry, free-base or acetate form, formula, mass, and lot identity.

The original isolation paper described thymosin alpha-1 as a 28-residue peptide obtained from calf thymus. It was one of several peptides present in thymosin fraction 5. That historical relationship explains the shared vocabulary; it does not make fraction 5 another name for the isolated molecule. The abstract establishes the identity distinction without establishing a modern clinical indication. Goldstein and colleagues, 1977

What has been studied in cells and animals?

FDA reviewed biochemical, cell, and animal studies involving immune-signaling endpoints. The agency also explained why those findings are difficult to translate: models and exposures varied, and some experimental concentrations were far removed from human-study exposure.[1]

Mechanistic language should stay narrow. “Studied in immune-signaling models” is supportable when tied to a source. “Boosts immunity,” “fights infections,” “stops cancer,” or “improves wellness” exceeds the evidence.

Evidence tier: E, Laboratory evidence or D, Animal evidence, depending on the cited experiment.

Romani and colleagues' 2004 study investigated responses to Aspergillus fumigatus. The primary abstract reports maturation and interleukin-12 production in fungus-pulsed dendritic cells, with signalling involving MyD88-dependent pathways. In the animal experiments, synthetic thymosin alpha-1 promoted antifungal T-helper type 1 responses and myeloid recovery and protected susceptible mice that had received hematopoietic transplants. Primary study abstract

The favorable finding belongs to that experimental configuration. The subject was not an unselected healthy animal facing an unspecified infection, and the endpoint was not a general score for immune strength. Keeping the fungal challenge and transplant context visible makes the result more scientifically useful, even though it makes the promotional claim less sweeping.

Only the abstract was available for this appraisal. It does not provide enough detail to independently assess all allocation procedures, blinding, animal numbers, handling of exclusions, or the complete survival analysis. Accordingly, this article does not supply an effect size or claim that methodological quality has been fully established.

What did the earlier sepsis trial report?

The 2013 ETASS study randomized 361 participants with severe sepsis across six hospitals in China. It reported a possible mortality signal, but the statistical interpretation was borderline: one analysis crossed the conventional significance threshold, another did not, and the relative-risk confidence interval included no effect.[2]

The study was single-blind and used definitions and clinical practice from an earlier era. Its result required confirmation in a larger, more rigorous trial.

Evidence tier: C, Limited and conflicting human evidence.

What did the large phase 3 trial find?

The 2025 TESTS trial was a multicenter, double-blind, placebo-controlled phase 3 study of 1,106 adults with sepsis at 22 centers in China. In the modified intention-to-treat analysis, 28-day all-cause mortality did not differ between groups. No secondary or safety outcome differed statistically.[3]

Prespecified subgroup analyses showed heterogeneity, but subgroup signals do not replace a null primary result and require independent confirmation.

Evidence tier: B, Human evidence for the narrow conclusion that this phase 3 trial did not show a clear reduction in 28-day mortality.

Newer observational evidence remains a different kind of test

An August 2026 report described a retrospective cohort of 327 people with tuberculosis-related sepsis. Thymosin alpha-1 use was associated with lower adjusted 28-day mortality, but the authors explicitly said causality could not be inferred. The accessed publisher page supplied the abstract and identified the report as an early accepted version. This finding raises a population-specific hypothesis; it does not overturn a randomized comparison in a different sepsis population. Wang and colleagues, primary abstract

A transplant report was exceptionally small

A 2013 report enrolled eight infected recipients of hematopoietic stem cell transplantation, including both allogeneic and autologous transplantation. The abstract describes random allocation of four people to treatment and four to control. Some cytokine measurements increased more with thymosin alpha-1, while several T-cell measurements did not significantly differ. The authors reported no induced acute or chronic graft-versus-host disease and interpreted the findings favorably. Ding and colleagues

That is a small randomized report, not simply an uncontrolled case series. Correctly identifying the design does not remove its limitations. With so few participants, one person's course can have a large influence on the apparent pattern. Cytokine differences do not by themselves establish better infection control, and absence of a particular complication in this sample cannot reliably exclude an uncommon risk.

Only the abstract was read for this appraisal. It does not permit an independent audit of concurrent therapies, allocation concealment, individual outcomes, or all safety surveillance. The authors' broad conclusion about safety should therefore remain attributed to them rather than become the review's own unrestricted conclusion.

What did FDA conclude about the broader evidence?

FDA’s 2024 review examined proposed uses across viral diseases, vaccine response, malignancies, sepsis, transplant settings, COPD, and ME/CFS. It concluded that the evidence was lacking and that studies were often limited by small samples, weak design, outdated control therapy, unclear endpoints, or heterogeneous populations.[1]

The review also found no evidence that Ta1 alone, or Ta1 added to other therapy, offered an advantage over current standard care for the uses evaluated. The large 2025 TESTS result was published after that FDA review and reinforces the need to present the null primary outcome prominently.

Current U.S. FDA and compounding status

FDA’s 2024 review stated that it had approved no drug products containing Ta1.[1] In December 2024, the Pharmacy Compounding Advisory Committee voted 4–17 against placing either Ta1 free base or Ta1 acetate on the 503A Bulks List, citing a lack of convincing effectiveness evidence.[4]

The committee’s vote is advice within a regulatory process; it is not a drug approval or, by itself, a final rule.

FDA’s current compounding safety-risk page says compounded Ta1 may present immunogenicity and peptide-characterization concerns and that available information is inadequate to fully understand the safety issues for the proposed compounded drug.[5]

Status checked: August 27, 2026.

A specific Singapore product record

The Singapore National Drug Formulary entry for Zadaxin Injection, registration SIN07483P, was updated on September 16, 2026. It lists a prescription product and indications involving chronic hepatitis B and chronic hepatitis C, with different monotherapy and interferon-combination wording. The entry is tied to a named product and licence holder. Singapore government product information

That record does not establish approval for general immune protection, post-viral symptoms, every infection, or healthy aging. It also does not make all materials labelled thymosin alpha-1 registered Zadaxin products. The difference is substantive: the authority's product record is more specific than a molecule appearing in an international catalog.

The formulary's general information directs readers to HSA's register for the most current product information. This appraisal inspected the government formulary entry, not a complete contemporaneous HSA dossier or every package-insert attachment. Its scope should remain limited accordingly. Formulary information boundary

The Singapore government product record for Zadaxin identifies hypersensitivity as a contraindication and flags deliberate immunosuppression, including organ transplantation, as a circumstance requiring particular clinical judgment. These are product-label boundaries, not a personalized recommendation or a statement that all immune disorders behave alike. Singapore National Drug Formulary, contraindications

Important evidence limits

• A peptide’s immune-signaling role does not establish a clinical outcome.
• The strongest recent sepsis trial had a null primary result.
• Earlier favorable signals were smaller, statistically borderline, or methodologically limited.
• Studies in one disease, population, formulation, or national standard of care cannot be generalized to another.
• Ta1 free base, Ta1 acetate, Zadaxin, a compounded drug, and a research vial are not interchangeable product records.
• No cited source establishes the identity, quantity, purity, stability, sterility, or performance of a Serum Research lot.

Frequently asked questions

Is thymalfasin another name for thymosin alpha-1?

FDA describes thymalfasin as chemically synthesized thymosin alpha-1 with the same amino-acid sequence. Product form and finished-product identity still require separate verification.

Is thymosin alpha-1 the same as thymosin beta-4?

No. They are different peptides with different sequences and evidence records. Findings for thymosin alpha-1 do not apply to thymosin beta-4 or TB-500.

Is thymosin alpha-1 FDA approved?

FDA’s 2024 review stated that no FDA-approved drug products contained Ta1. A foreign finished product, UNII, trial, or compounding nomination does not establish U.S. approval.

What did the large sepsis trial find?

The 2025 phase 3 TESTS trial did not find a clear difference in 28-day all-cause mortality, and its reported secondary outcomes were also not statistically different.

Did the advisory committee add Ta1 to the 503A Bulks List?

No. The committee voted against placing the free base and acetate on the list. The vote itself is advisory and should not be described as a final drug-approval decision.

Does this page explain how to use thymosin alpha-1?

No. It is an identity, evidence, and regulatory-status summary and intentionally provides no personal-use instructions.

Primary and official sources

1. FDA 2024 Pharmacy Compounding Advisory Committee review
2. Earlier randomized severe-sepsis trial, PMID 23327199
3. TESTS phase 3 trial, PMID 39814420
4. FDA PCAC vote summary
5. Current FDA compounding safety-risk page
6. FDA UNII record for thymalfasin, W0B22ISQ1C

Suggested internal links after publication: Research Library hub; how we review evidence; thymosin beta-4 versus TB-500; approved drug versus research material; quality testing. No catalog link until the gate below passes.